Parkinson`s disease, or paralysis agitans, is characterized by a resting tremor (involuntary trembling when a limb is in rest), rigidity (inability to initiate movements), and bradykinesia (slowness of movements). The disease results from the degeneration of dopaminergic neurons that arise in the substantial nigra and project to other structures in the basal ganglia.
(Or)
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra region of the brain. This results in motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Drugs used in the treatment of Parkinson’s disease aim to alleviate these symptoms by increasing dopamine levels in the brain or by targeting other neurotransmitter systems to compensate for dopamine deficiency.
Classification of Drugs used in Parkinson’s disease
Drugs used in Parkinson’s disease can be classified into several main categories based on their mechanism of action and therapeutic effects:
1. Levodopa Preparations: Levodopa is the most effective medication for treating the motor symptoms of Parkinson’s disease. Levodopa is converted to dopamine in the brain and replenishes dopamine levels in the striatum, alleviating motor symptoms. Levodopa is often combined with a peripheral decarboxylase inhibitor (such as carbidopa or benserazide) to prevent its conversion to dopamine in the bloodstream, thereby increasing its availability in the brain.
2. Dopamine Agonists: Dopamine agonists directly stimulate dopamine receptors in the brain, bypassing the need for dopamine synthesis. These medications are less effective than levodopa but are often used as adjunctive therapy or as initial treatment in younger patients to delay levodopa therapy. Examples of dopamine agonists include pramipexole, ropinirole, rotigotine, and apomorphine.
3. Monoamine Oxidase-B (MAO-B) Inhibitors: MAO-B inhibitors prevent the breakdown of dopamine by inhibiting the enzyme monoamine oxidase-B, which metabolizes dopamine in the brain. These medications can help increase dopamine levels in the brain and prolong the effects of levodopa. Examples of MAO-B inhibitors include selegiline and rasagiline.
4. Catechol-O-Methyltransferase (COMT) Inhibitors: COMT inhibitors block the enzyme catechol-O-methyltransferase, which metabolizes levodopa in the peripheral tissues, thereby increasing levodopa’s availability in the brain. These medications are often used as adjunctive therapy with levodopa/carbidopa to prolong the duration of its effects. Examples of COMT inhibitors include entacapone, tolcapone, and opicapone.
5. Anticholinergic Agents: Anticholinergic medications block the action of acetylcholine in the brain, which can help alleviate tremors and rigidity in some patients with Parkinson’s disease. These medications are typically used as adjunctive therapy and are more effective for controlling tremors than other motor symptoms. Examples of anticholinergic agents include trihexyphenidyl and benztropine.
6. Amantadine: Amantadine is an antiviral medication with mild antiparkinsonian effects. Its mechanism of action in Parkinson’s disease is not fully understood, but it is believed to involve increasing dopamine release and blocking glutamate receptors in the brain. Amantadine is often used as adjunctive therapy to alleviate dyskinesias (involuntary movements) associated with levodopa therapy.
Mechanism of Action of Drugs used in Parkinson’s disease
The mechanism of action of drugs used in Parkinson’s disease varies depending on the specific medication:
1. Levodopa Preparations: Levodopa is a precursor of dopamine and is converted to dopamine in the brain by the enzyme aromatic L-amino acid decarboxylase (AADC). Dopamine produced from levodopa replenishes dopamine levels in the striatum, improving motor symptoms.
2. Dopamine Agonists: Dopamine agonists directly stimulate dopamine receptors in the brain, particularly dopamine D2 receptors. By mimicking the action of dopamine, these medications alleviate motor symptoms of Parkinson’s disease.
3. MAO-B Inhibitors: MAO-B inhibitors prevent the breakdown of dopamine by inhibiting the enzyme monoamine oxidase-B, which metabolizes dopamine in the brain. This leads to increased dopamine levels in the brain and prolonged effects of endogenous dopamine and exogenous levodopa.
4. COMT Inhibitors: COMT inhibitors block the enzyme catechol-O-methyltransferase, which metabolizes levodopa in the peripheral tissues. By inhibiting this enzyme, COMT inhibitors increase levodopa’s availability in the brain and prolong its duration of action.
5. Anticholinergic Agents: Anticholinergic medications block the action of acetylcholine in the brain, which can help alleviate tremors and rigidity by rebalancing the cholinergic-dopaminergic system.
6. Amantadine: The exact mechanism of action of amantadine in Parkinson’s disease is not fully understood. It is believed to involve increasing dopamine release and blocking glutamate receptors, thereby modulating neurotransmission in the brain and alleviating motor symptoms.
Side Effects of Drugs used in Parkinson’s disease
While drugs used in Parkinson’s disease can effectively alleviate motor symptoms, they are associated with a range of side effects, which can vary depending on the specific medication and individual patient factors:
1. Levodopa Preparations:
Dyskinesias: Involuntary movements such as chorea, dystonia, and peak-dose dyskinesias can occur, especially with long-term use.
Nausea, vomiting, and orthostatic hypotension are common side effects, particularly during the initial titration period.
Psychiatric side effects such as hallucinations, confusion, and impulse control disorders may occur, especially at higher doses.
2. Dopamine Agonists:
Nausea, vomiting, and orthostatic hypotension are common side effects, particularly during the initial titration period.
Psychiatric side effects such as hallucinations, impulse control disorders, and compulsive behaviors (e.g., gambling, hypersexuality) may occur, especially with higher doses or long-term use.
Dopamine agonists are associated with a higher risk of impulse control disorders compared to other antiparkinsonian medications.
3. MAO-B Inhibitors:
MAO-B inhibitors are generally well-tolerated, but side effects may include nausea, headache, insomnia, and gastrointestinal disturbances.
Selegiline may interact with certain medications and foods containing tyramine, leading to hypertensive crisis (cheese effect).
4. COMT Inhibitors:
COMT inhibitors may cause gastrointestinal side effects such as diarrhea, abdominal pain, and dyspepsia.
Tolcapone is associated with a higher risk of hepatotoxicity and requires regular monitoring of liver function.
5. Anticholinergic Agents:
Anticholinergic medications can cause dry mouth, blurred vision, urinary retention, constipation, and cognitive impairment (especially in elderly patients).
They may exacerbate cognitive impairment and increase the risk of falls in elderly patients with Parkinson’s disease.
6. Amantadine:
Common side effects of amantadine include dizziness, insomnia, nausea, and confusion.
Long-term use of amantadine may be associated with livedo reticularis (a mottled discoloration of the skin) and peripheral edema.
Conclusion:
Drugs used in Parkinson’s disease play a crucial role in alleviating motor symptoms and improving the quality of life for patients with this neurodegenerative disorder. These medications include levodopa preparations, dopamine agonists, MAO-B inhibitors, COMT inhibitors, anticholinergic agents, and amantadine, each with its own mechanism of action and side effect profile. Treatment decisions should be individualized based on the patient’s age, disease severity, comorbidities, and medication tolerance, with close monitoring for efficacy and side effects. A multidisciplinary approach involving neurologists, movement disorder specialists, and other healthcare professionals is essential for optimal management of Parkinson’s disease.
Visit: Pharmacareerinsider.com
